Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 18444808.
- Also identified by DOI 10.1086/529388.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The immunomodulatory drug lenalidomide is currently being evaluated for its antineoplastic properties in treating hematologic malignancies. However, its potential role in augmenting immune reactions against opportunistic infections has not been explored. We report the rapid resolution of chronic Mycobacterium marinum infection in a patient following initiation of lenalidomide therapy for chronic lymphocytic leukemia.
Medical subject headings
- Antineoplastic Agents
- Leukemia, Lymphocytic, Chronic, B-Cell
- Mycobacterium Infections, Nontuberculous
- Mycobacterium marinum
- Skin Diseases, Bacterial
- Thalidomide